Neuren Pharmaceuticals【NEU】銘柄情報

Neuren Pharmaceuticals Limited (NEU) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

16.66

( -2.00% )

買値

16.64

売値

16.75

出来高

524,705

16.53 日の範囲 17.20

11.00 52 週間の範囲 22.985

時価総額

2.105B

前日終値

17.00

始値

16.99

時刻

16.74

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

AUD 388,157

発行済株式数

126,323,976

配当利回り

PER

71.34

1 株当たり利益 (EPS)

0.23

歳入

64.65M

純利益

30.44M

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical tr... Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.neurenpharma.com

本社

Hawthorn East, Australia

設立

2026

Neuren Pharmaceuticals Limited is listed in the Healthcare sector of the オーストラリア証券取引所 with ticker NEU. The last closing price for Neuren Pharmaceuticals was AUD17. Over the last year, Neuren Pharmaceuticals shares have traded in a share price range of AUD 11.00 to AUD 22.985.

Neuren Pharmaceuticals currently has 126,323,976 shares in issue. The market capitalisation of Neuren Pharmaceuticals is AUD2.10 billion. Neuren Pharmaceuticals has a price to earnings ratio (PE ratio) of 71.34.

ACADIA Pharmaceuticals & Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment...

With No Approved Treatments in Rett Syndrome, FDA Decision Highlights Significant Unmet Need ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and...

FDA Grants Orphan Drug Designation for Neuren's NNZ-2591 to Treat Angelman, Phelan-McDermid and Pitt Hopkins Syndromes

Neuren Pharmaceuticals (ASX: NEU) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren’s...

Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the A...

-- Statistically Significant Improvement Indicates Trofinetide’s Potential for Treating Rett Syndrome-- Trofinetide for Rett Syndrome has...

ACADIA Pharmaceuticals & Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development & Com...

-ACADIA plans to initiate a Phase 3 study of trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental congenital CNS...

American Stock Exchange to Trade Options on Five New Securities

NEW YORK, April 12 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) will launch trading in options on Thursday, April 13, 2006 on the...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	3.67	28.2525019246	12.99	18.85	12.07	1206265	16.07144583	DE
4	3.22	23.9583333333	13.44	18.85	12.07	640922	14.51837935	DE
12	3.96	31.1811023622	12.7	18.85	11.68	414967	13.72199657	DE
26	-1.95	-10.4782375067	18.61	21.04	11	454835	13.78684377	DE
52	2.29	15.9359777314	14.37	22.985	11	449825	16.24663141	DE
156	4.41	36	12.25	170.09	8.61	517487	15.42900406	DE
260	15.05	934.782608696	1.61	170.09	1.51	458242	12.87824197	DE